nach oben

CNS Drugs

Erschienen in:

01.06.2009 | Review Article

Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy

verfasst von: Sura Alwan, Jan M. Friedman

Erschienen in: CNS Drugs | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are among the most commonly used medications, with a prescription frequency of 2.3% in pregnant women. Although most babies born to women who take SSRIs during pregnancy are normal, there is accumulating evidence that maternal SSRI treatment during pregnancy may cause adverse reproductive outcomes. Maternal SSRI treatment during the first trimester has been implicated in increased risks of birth defects, specifically cardiac abnormalities, in the infant, whereas third-trimester treatment has been linked to various neonatal complications, including symptoms of neonatal withdrawal and toxicity, prematurity, low birth weight and persistent pulmonary hypertension of the newborn. Although data on neurobehavioural and long-term cognitive problems among children of women who were treated with SSRIs during pregnancy remain limited, the possibility of such functional abnormalities is an additional concern.

On the other hand, untreated maternal depression also carries serious risks for both the mother and the baby, and SSRIs are one of the best available treatments. Thus, pregnant women who require treatment for depression and their physicians often face a difficult choice regarding the use of SSRIs.

Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999; 282: 1264–9PubMedCrossRef

Ryan D, Milis L, Misri N. Depression during pregnancy. Can Fam Physician 2005 Aug; 51: 1087–93PubMed

Wadhwa PD, Sandman CA, Porto M, et al. The association between prenatal stress and infant birth weight and gestational age at birth: a prospective investigation. Am J Obstet Gynecol 1993; 169: 858–65PubMed

Chung TK, Lau TK, Yip AS, et al. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 2001; 63(5): 830–4PubMed

Hobel CJ, Goldstein A, Barrett ES. Psychosocial stress and pregnancy outcome. Clin Obstet Gynecol 2008; 51(2): 333–48PubMedCrossRef

Moses-Kolko EL, Roth EK. Antepartum and postpartum depression: healthy mom, healthy baby. J Am Med Womens Assoc 2004; 59(3): 181–91PubMed

Mann JJ. The medical management of depression. N Engl J Med 2005; 353: 1819–34PubMedCrossRef

Reefhuis J, Rasmussen SA, Friedman JM. Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 2188–90PubMedCrossRef

Preskorn SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry 1994; 55 Suppl. A: 6–22PubMed

10.

Morrison JL, Riggs KW, Rurak DW. Fluoxetine during pregnancy: impact on fetal development. Reprod Fertil Dev 2005; 17(6): 641–50PubMedCrossRef

11.

Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11–28PubMedCrossRef

12.

US Food Drug Administration. FDA Public Health Advisory: paroxetine 2005 [online]. Available from URL: http://www.fda.gov/cder/drug/advisory/paroxetine200512.htm [Accessed 2008 Jan 18]

13.

Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006; 21: 221–2PubMedCrossRef

14.

Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16(10): 1075–85PubMedCrossRef

15.

US Food Drug Administration. FDA Public Health Advisory: treatment challenges of depression in pregnancy and the possibility of persistent pulmonary hypertension in newborns 2006 [online]. Available from URL: http://www.fda.gov/cder/drug/advisory/SSRI_PPHN200607.htm [Accessed 2008 Jan 18]

16.

Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269: 2246–8PubMedCrossRef

17.

Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010–5PubMedCrossRef

18.

Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279: 609–10PubMedCrossRef

19.

Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicenter, controlled, observational study. Br J Clin Pharmacol 2008; 66(5): 695–705PubMed

20.

Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy: HMO Research Network Center for Education, Research in Therapeutics. Pharmacoepidemiol Drug Saf 2007; 16(10): 1086–94PubMedCrossRef

21.

Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055–61PubMedCrossRef

22.

Wogelius P, Norgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006; 17(6): 701–4PubMedCrossRef

23.

Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006 Apr; 194(4): 961–6PubMedCrossRef

24.

Källén BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A 2007; 79(4): 301–8CrossRef

25.

Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005; 106: 1289–96PubMedCrossRef

26.

Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80(1): 18–27PubMedCrossRef

27.

Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects: National Birth Defects Prevention Study. N Engl J Med 2007; 256(26): 2684–92CrossRef

28.

Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356(26): 2675–83PubMedCrossRef

29.

Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B 2008; 83: 68–76CrossRef

30.

Ramos E, St-Andre M, Rey E, et al. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 2008; 192: 344–50PubMedCrossRef

31.

Wichman CL, Moore KM, Lang TR, et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009; 84(1): 23–7PubMedCrossRef

32.

Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55: 503–8PubMedCrossRef

33.

Kallen B. Fluoxetine use in early pregnancy. Birth Defects Res B 2004; 71: 395–6CrossRef

34.

Daniel WA. Mechanisms of cellular distribution of psychotropic drugs: significance for drug action and interactions. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 65–73PubMedCrossRef

35.

Hansen D, Lou HC, Olsen J. Serious life events and congenital malformations: a national study with complete follow-up. Lancet 2000; 356(9233): 875–80PubMedCrossRef

36.

Carmichael SL, Shaw GM. Maternal life event stress and congenital anomalies. Epidemiology 2000 Jan; 11(1): 30–5PubMedCrossRef

37.

Nimby GT, Lundberg L, Sveger T, et al. Maternal distress and congenital malformations: do mothers of malformed fetuses have more problems? J Psychiatr Res 1999 Jul–Aug; 33(4): 291–301PubMedCrossRef

38.

Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007; 29(5): 918–26PubMedCrossRef

39.

Bellantuono C, Migliarese G, Gentile S. Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review. Hum Psychopharmacol 2007; 22(3): 121–8PubMedCrossRef

40.

Greene MF. Teratogenicity of SSRIs: serious concern or much ado about little? N Engl J Med 2007 Jun; 356(26): 2732–3PubMedCrossRef

41.

Diav-Citrin O, Shechtman S, Weinbaum D. Pregnancy outcome after gestational exposure to paroxetine: a prospective controlled study cohort. Teratology 2002; 65(6): 298

42.

Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol 2006 May; 22(4): 571–5PubMedCrossRef

43.

Hemels ME, Einarson A, Koren G, et al. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother 2005 Mar; 39(5): 803–9PubMedCrossRef

44.

Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002; 156(11): 1129–32PubMedCrossRef

45.

Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006 Aug; 63(8): 898–906PubMedCrossRef

46.

Kallen B. Neonate characteristics after maternal use of anti-depressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158: 307–8CrossRef

47.

Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142(4): 402–8PubMedCrossRef

48.

Cohen LS, Heller VL, Bailey JW, et al. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000; 48(10): 996–1000PubMedCrossRef

49.

Laine K, Heikkinin T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60(7): 720–6PubMedCrossRef

50.

Oberlander TF, Misri S, Fitzgerald CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004; 65(2): 230–7PubMedCrossRef

51.

Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293(19): 2372–83PubMedCrossRef

52.

Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006 Feb; 160(2): 173–6PubMedCrossRef

53.

Austin MP. To treat or not to treat: maternal depression, SSRI use in pregnancy and adverse neonatal effects. Psychol Med 2006 Dec; 36(12): 1663–70PubMedCrossRef

54.

Oberlander TF, Warburton W, Misri S, et al. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 2008; 192: 338–43PubMedCrossRef

55.

Isbister GK, Dawson A, Whyte IM, et al. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch Dis Child Fetal Neonatal Ed 2001 Sep; 85(2): F147–8PubMedCrossRef

56.

Haddad PM. Antidepressant discontinuation syndromes. Drug Saf 2001; 24(3): 183–97PubMedCrossRef

57.

Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996 Oct; 16(5): 356–62PubMedCrossRef

58.

Sistonen J, Sajantila A, Lao O, et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007; 17(2): 93–101PubMed

59.

Miksys S, Rao Y, Hoffmann E, et al. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 2002 Sep; 82(6): 1376–87PubMedCrossRef

60.

Laine K, Kytölä J, Bertilsson L. Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit 2004 Dec; 26(6): 685–7PubMedCrossRef

61.

Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23(5): 587–90PubMedCrossRef

62.

Oberlander TF, Bonaguro RJ, Misri S, et al. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Molecular Psychiatry 2008 May; 13: 65–73PubMedCrossRef

63.

Suri R, Altshuler L, Hellemann G, et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007 Aug; 164(8): 1206–13PubMedCrossRef

64.

Maschi S, Clavenna A, Campi R, et al. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG 2008 Jan; 115(2): 283–9PubMedCrossRef

65.

Pearson KH, Nonacs RM, Viguera AC, et al. Birth outcomes following prenatal exposure to antidepressants. J Clin Psychiatry 2007 Aug; 68(8): 1284–9PubMedCrossRef

66.

Hendrick V, Stowe ZN, Altshuler LL, et al. Placental passage of antidepressant medications. Am J Psychiatry 2003; 160: 993–6PubMedCrossRef

67.

Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579–87PubMedCrossRef

68.

Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008; 17(8): 801–6PubMedCrossRef

69.

Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004; 113(2): 368–75PubMedCrossRef

70.

Oberlander TF, Eckstein Grunau R, Fitzgerald C, et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 2002; 51: 443–53PubMedCrossRef

71.

Oberlander TF, Grunau RE, Fitzgerald C, et al. Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 2005; 115: 411–25PubMedCrossRef

72.

Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome: review of the literature and preliminary findings. Epidemiol Rev 1995; 17: 165–71PubMed

73.

Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 4: 258–62CrossRef

74.

Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159(11): 1889–95PubMedCrossRef

75.

Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002 Aug; 72(2): 184–91PubMedCrossRef

76.

Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003 Apr; 73(4): 330–7PubMedCrossRef

77.

Misri S, Reebye P, Kendrick K, et al. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry 2006 Jun; 163(6): 1026–32PubMedCrossRef

78.

Oberlander TF, Reebye P, Misri S, et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor anti-depressant during pregnancy. Arch Pediatr Adolesc Med 2007 Jan; 161(1): 22–9PubMedCrossRef

79.

Herlenius E, Lagercrantz H. Neurotransmitters and neuro-modulators during early human development. Early Hum Dev 2001 Oct; 65(1): 21–37PubMedCrossRef

80.

Buznikov GA, Lambert HW, Lauder JM. Serotonin and serotonin-like substances as regulators of early embryogenesis and morphogenesis. Cell Tissue Res 2001; 305: 177–86PubMedCrossRef

81.

Moiseiwitsch JR, Lauder JM. Serotonin regulates mouse cranial neural crest migration. Proc Natl Acad Sci U S A 1995; 92: 7182–6PubMedCrossRef

82.

Yavarone MS, Shuey DL, Tamir H, et al. Serotonin and cardiac morphogenesis in the mouse embryo. Teratology 1993; 47: 573–84PubMedCrossRef

83.

Shuey DL, Sadler TW, Tamir H, et al. Serotonin and morphogenesis: transient expression of serotonin uptake and binding protein during craniofacial morphogenesis in the mouse. Anat Embryol (Berl) 1993; 187: 75–85CrossRef

84.

Choi DS, Kellermann O, Richard S, et al. Mouse 5-HT2B receptor-mediated serotonin trophic functions. Ann N Y Acad Sci 1998; 861: 67–73PubMedCrossRef

85.

Sari Y, Zhou FC. Serotonin and its transporter on proliferation of fetal heart cells. Int J Dev Neuroscience 2003; 21: 417–24CrossRef

86.

Davies TS, Kluwe WM. Preclinical toxicological evaluation of sertraline hydrochloride. Drug Chem Toxicol 1998; 21: 521–37PubMedCrossRef

87.

Baldwin JA, Davidson EJ, Pritchard AL, et al. The reproductive toxicology of paroxetine. Acta Psychiatr Scand 1989; 80 Suppl. 350: 37–9CrossRef

88.

Byrd RA, Markham JK. Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits. Fundam Appl Toxicol 1994; 22: 511–8PubMedCrossRef

89.

Stewart JD, Rayburn WF, Gonzalez CL, et al. Impact of antenatal paroxetine (Paxil) exposure on perinatal and neonatal outcomes of mice. Neurotoxicol Teratol 1998; 20(3): 365–6

90.

Vorhees CV, Acuff-Smith KD, Schilling MA, et al. A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 1994 Aug; 23(2): 194–205PubMedCrossRef

91.

Hallberg P, Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol 2005; 25: 59–73PubMedCrossRef

92.

Hansson SR, Mezey E, Hoffman BJ. Serotonin transporter messenger RNA expression in neural crest-derived structures and sensory pathways of the developing rat embryo. Neuroscience 1999; 89(1): 243–65PubMedCrossRef

93.

Singh Y, Jaiswal AK, Singh M, et al. Effect of prenatal diazepam, phenobarbital, haloperidol and fluoxetine exposure on foot shock induced aggression in rats. Indian J Exp Biol 1998 Oct; 36(10): 1023–4PubMed

94.

Crowley JM, Dopheide M, Countryman RA, et al. Early developmental exposure to fluoxetine (Prozac): enduring effects on learning, memory, and aggression. Neurotoxicol Teratol 2001; 23(3): 289

95.

Coleman FH, Christensen HD, Gonzalez CL, et al. Behavioral changes in developing mice after prenatal exposure to paroxetine (Paxil). Am J Obstet Gynecol 1999 Nov; 181(5 Pt 1): 1166–71PubMedCrossRef

96.

Nonacs R, Cohen LS. Assessment and treatment of depression during pregnancy: an update. Psychiatr Clin North Am 2003; 26: 547–62PubMedCrossRef

Titel: Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy
verfasst von: Sura Alwan
Jan M. Friedman
Publikationsdatum: 01.06.2009
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 6/2009
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200923060-00004

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2009

Neuroleptic Malignant Syndrome Associated with Atypical Antipsychotic Drugs

Prescription of Heroin for the Management of Heroin Dependence

Improving Compliance with Interferon-β Therapy in Patients with Multiple Sclerosis

Aripiprazole Monotherapy in Children and Young Adolescents with Pervasive Developmental Disorders